HHS Proposes Mandatory GRAS Notices - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

HHS Proposes Mandatory GRAS Notices

Manufacturers would be required to notify the FDA of GRAS determinations under a proposed rule, while HHS and USDA also submitted the first proposed federal definition of ultra-processed foods for final review.

  • By

  • Kathryn Wighton

  • August 10, 2026

  • 3 min

Share

Objective:

To improve food ingredient oversight and enhance transparency regarding substances added to the food supply.

Approach:
  • GRAS Notification Requirement: Manufacturers would be required to notify the FDA when they determine a substance is Generally Recognized as Safe.
  • Definition of Ultra-Processed Foods: The HHS and USDA submitted a proposed definition of ultra-processed foods for final review to improve consistency in federal nutrition research.
Key Findings:
  • Nearly 60% of the American diet consists of ultra-processed foods.
  • Childhood obesity affects more than one in five American children.
  • The absence of a standardized federal definition for UPFs has limited consistency in nutrition research.
Interpretation:

Limitations:
  • The current GRAS framework allows manufacturers to self-determine safety without mandatory notification.
Conclusion:

Sources:

Original Source(s)

HHS Proposes Mandatory GRAS Notices

  • by Kathryn Wighton

  • August 10, 2026

Related Content

Elastography Distinguishes Cardiac Amyloidosis Types

Shear wave velocity measurements in the basal anteroseptal and right ventricular walls differed between transthyretin and light chain cardiac amyloidosis when conventional echocardiographic parameters did not.

PTSD May Be Linked to Accelerated Aging

Integrated proteomic and metabolomic analyses identified redox-metabolic signatures associated with chronic posttraumatic stress disorder and accelerated biological aging across multiple organ systems.

FDA Names PreCheck Participants

Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.